PTC Therapeutics (PTCT)


Market Price (11/19/2026): $59.91 | Market Cap: $5.0 BilSector: Health Care | Industry: Pharmaceuticals

PTC Therapeutics (PTCT)


Market Price (11/19/2026): $59.91
Market Cap: $5.0 Bil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -30%

Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -35%

Low stock price volatility
Vol 12M is 43%

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more.

Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 44x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 479x

Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -35%

Not cash flow generative
FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3.6%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.3%

Key risks
PTCT key risks include [1] significant revenue concentration in a few key products, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -30%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -35%
2 Low stock price volatility
Vol 12M is 43%
3 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more.
4 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 44x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 479x
5 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -35%
6 Not cash flow generative
FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3.6%
7 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.3%
8 Key risks
PTCT key risks include [1] significant revenue concentration in a few key products, Show more.

PTCT in ETFs

Weight = PTCT's share of each fund

VTI0.01%
ITOT0.01%
IWM0.18%
IJR0.30%
VB0.06%
XBI1.4%
SLYG0.65%
IJT0.63%
+14 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/18/2026

Nov 3: up 11.9% in one day (S&P 500 up 0.3%)
This day's gain came without company news in our feed. The broader market also rose slightly.

Down 33.8% from its Jul 9 high to Oct 16 (S&P 500 up 1.8%)
This decline was largely driven by the release of Q2 earnings analysis on July 31, which coincided with a sharp daily fall. The stock also fell on July 10 without company news.

Oct 30: down 7.0% the day after its Oct 29 earnings report (S&P 500 down 1.8%)
The decline followed its third quarter earnings report, which showed sharply lower net income and diluted EPS compared to a year earlier. The broader market also fell that day.

Show more
Prices as of 11/18/2026

Nov 3: up 11.9% in one day (S&P 500 up 0.3%)
This day's gain came without company news in our feed. The broader market also rose slightly.

Down 33.8% from its Jul 9 high to Oct 16 (S&P 500 up 1.8%)
This decline was largely driven by the release of Q2 earnings analysis on July 31, which coincided with a sharp daily fall. The stock also fell on July 10 without company news.

Oct 30: down 7.0% the day after its Oct 29 earnings report (S&P 500 down 1.8%)
The decline followed its third quarter earnings report, which showed sharply lower net income and diluted EPS compared to a year earlier. The broader market also fell that day.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -11.4% change in PTCT stock from 7/31/2026 to 11/18/2026 was primarily driven by a -22.3% change in the company's P/S Multiple.
(LTM values as of)731202611182026Change
Stock Price ($)68.0160.23-11.4%
Change Contribution By: 
Total Revenues ($ Mil)1,0091,15614.6%
P/S Multiple5.64.4-22.3%
Shares Outstanding (Mil)8383-0.6%
Cumulative Contribution-11.4%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/18/2026
ReturnCorrelation
PTCT-11.4% 
Market (SPY)-2.0%35.9%
Sector (XLV)11.9%35.3%

Fundamental Drivers

The -7.4% change in PTCT stock from 4/30/2026 to 11/18/2026 was primarily driven by a -33.2% change in the company's Total Revenues ($ Mil).
(LTM values as of)430202611182026Change
Stock Price ($)65.0660.23-7.4%
Change Contribution By: 
Total Revenues ($ Mil)1,7311,156-33.2%
P/S Multiple3.14.440.8%
Shares Outstanding (Mil)8283-1.5%
Cumulative Contribution-7.4%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/18/2026
ReturnCorrelation
PTCT-7.4% 
Market (SPY)2.1%19.7%
Sector (XLV)25.1%21.1%

Fundamental Drivers

The -11.8% change in PTCT stock from 10/31/2025 to 11/18/2026 was primarily driven by a -34.5% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202511182026Change
Stock Price ($)68.3160.23-11.8%
Change Contribution By: 
Total Revenues ($ Mil)1,7651,156-34.5%
P/S Multiple3.04.443.8%
Shares Outstanding (Mil)7883-6.4%
Cumulative Contribution-11.8%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/18/2026
ReturnCorrelation
PTCT-11.8% 
Market (SPY)8.2%26.8%
Sector (XLV)27.7%32.1%

Fundamental Drivers

The 221.2% change in PTCT stock from 10/31/2023 to 11/18/2026 was primarily driven by a 145.7% change in the company's P/S Multiple.
(LTM values as of)1031202311182026Change
Stock Price ($)18.7560.23221.2%
Change Contribution By: 
Total Revenues ($ Mil)7981,15644.8%
P/S Multiple1.84.4145.7%
Shares Outstanding (Mil)7583-9.7%
Cumulative Contribution221.2%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/18/2026
ReturnCorrelation
PTCT221.2% 
Market (SPY)81.1%30.7%
Sector (XLV)52.9%30.6%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
PTCT Return-35%-4%-28%64%68%-21%-1%
Peers Return-19%13%1%-12%-22%2%-35%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
PTCT Win Rate33%58%42%83%58%36% 
Peers Win Rate45%57%43%40%53%53% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
PTCT Max Drawdown-49%-43%-69%-24%-37%-34% 
Peers Max Drawdown-42%-31%-35%-34%-46%-31% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: SRPT, BIIB, BMRN, RARE, VRTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/18/2026 (YTD)

How Low Can It Go

EventPTCTS&P 500
2025 US Tariff Shock
  % Loss-28.2%-18.8%
  % Gain to Breakeven39.3%23.1%
  Time to Breakeven28 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-53.5%-9.5%
  % Gain to Breakeven114.8%10.5%
  Time to Breakeven200 days24 days
2023 SVB Regional Banking Crisis
  % Loss-12.5%-6.7%
  % Gain to Breakeven14.2%7.1%
  Time to Breakeven503 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-39.9%-24.5%
  % Gain to Breakeven66.3%32.4%
  Time to Breakeven22 days427 days
2020 COVID-19 Crash
  % Loss-45.5%-33.7%
  % Gain to Breakeven83.4%50.9%
  Time to Breakeven233 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-34.1%-19.2%
  % Gain to Breakeven51.8%23.8%
  Time to Breakeven212 days105 days

Compare to SRPT, BIIB, BMRN, RARE, VRTX

In The Past

PTC Therapeutics's stock fell -28.2% during the 2025 US Tariff Shock. Such a loss loss requires a 39.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventPTCTS&P 500
2025 US Tariff Shock
  % Loss-28.2%-18.8%
  % Gain to Breakeven39.3%23.1%
  Time to Breakeven28 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-53.5%-9.5%
  % Gain to Breakeven114.8%10.5%
  Time to Breakeven200 days24 days
2022 Inflation Shock & Fed Tightening
  % Loss-39.9%-24.5%
  % Gain to Breakeven66.3%32.4%
  Time to Breakeven22 days427 days
2020 COVID-19 Crash
  % Loss-45.5%-33.7%
  % Gain to Breakeven83.4%50.9%
  Time to Breakeven233 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-34.1%-19.2%
  % Gain to Breakeven51.8%23.8%
  Time to Breakeven212 days105 days
2016-2017 Trump Reflation Bond Selloff
  % Loss-64.3%-3.7%
  % Gain to Breakeven180.0%3.9%
  Time to Breakeven11 days6 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-86.7%-12.2%
  % Gain to Breakeven649.1%13.9%
  Time to Breakeven824 days62 days
2014-2016 Oil Price Collapse
  % Loss-28.4%-6.8%
  % Gain to Breakeven39.7%7.3%
  Time to Breakeven797 days15 days

Compare to SRPT, BIIB, BMRN, RARE, VRTX

In The Past

PTC Therapeutics's stock fell -28.2% during the 2025 US Tariff Shock. Such a loss loss requires a 39.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About PTC Therapeutics (PTCT)

PTC Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of medicines for patients suffering from rare genetic disorders. The company maintains a comprehensive portfolio ranging from commercialized therapies to candidates in various stages of clinical and preclinical development, focusing on addressing significant unmet medical needs.

The core of PTC's commercial offerings includes treatments for Duchenne muscular dystrophy (DMD): Translarna, available in the European Economic Area, Brazil, and Russia, and Emflaza, marketed in the United States. Additionally, PTC commercializes Tegsedi and Waylivra for other rare diseases across Latin America and the Caribbean, and Evrysdi for spinal muscular atrophy (SMA) in Brazil, often leveraging strategic collaborations to expand market access.

Beyond its current commercial products, PTC Therapeutics is actively advancing its pipeline, notably with PTC518, a promising candidate for Huntington's disease, developed using its innovative splicing platform. Through its commitment to scientific innovation and global collaborations, PTC Therapeutics aims to provide life-changing therapies to patients with rare diseases across diverse geographic markets.

AI Analysis | Feedback

Analogy 1: A BioMarin Pharmaceutical for a diverse set of rare diseases.

Analogy 2: A Vertex Pharmaceuticals, specializing in a wider range of rare genetic disorders.

AI Analysis | Feedback

  • Translarna: A medicine for the treatment of Duchenne muscular dystrophy, including nonsense mutation Duchenne muscular dystrophy.
  • Emflaza: A commercial product used for the treatment of Duchenne muscular dystrophy.
  • Tegsedi: Commercialized for the treatment of various rare diseases.
  • Waylivra: Commercialized for the treatment of various rare diseases.
  • Evrysdi: Marketed for the treatment of spinal muscular atrophy in adults and children.
  • PTC518: A product candidate under development for the treatment of Huntington's disease.

AI Analysis | Feedback

PTC Therapeutics, Inc. (PTCT) primarily sells its pharmaceutical products to individuals (patients) suffering from rare disorders. Based on the company description, its major customer categories are:

  1. Individuals with Duchenne muscular dystrophy (DMD)
  2. Individuals with Spinal Muscular Atrophy (SMA)
  3. Individuals with other rare diseases targeted by commercialized products such as Tegsedi and Waylivra

AI Analysis | Feedback

null

AI Analysis | Feedback

Matthew B. Klein, M.D., M.S., F.A.C.S. Chief Executive Officer

Dr. Klein has served as Chief Executive Officer of PTC Therapeutics since March 2023. He joined PTC in October 2019, holding various leadership roles including Global Head, Gene and Mitochondrial Therapies, Global Head, Clinical Development, Chief Development Officer, and Chief Operating Officer. Before joining PTC, Dr. Klein was the Chief Executive Officer and Chief Medical Officer of BioElectron Technology Corporation from 2018 to 2019, a biotechnology company focused on rare diseases, which was subsequently acquired by PTC in 2019. He also previously held the position of Senior Vice President, Clinical Science at BioElectron from 2012 to 2013. Dr. Klein has served on the board of directors of ClearPoint Neuro, Inc. since 2020.

Pierre Gravier Chief Financial Officer

Mr. Gravier was appointed Chief Financial Officer of PTC Therapeutics in July 2023. He brings over 17 years of experience as an investment banker, venture capitalist, and scientist. Prior to joining PTC, Mr. Gravier was a managing director in the healthcare group of Perella Weinberg Partners from 2013 to 2023, where he advised companies in the biopharmaceutical and pharmaceutical sectors on finance strategy and corporate development. Before Perella Weinberg, he worked as a healthcare investment banker at Barclays Capital in London from 2009 to 2013. He also served as a venture capital analyst at Société Générale Asset Management in Paris, focusing on early-stage biotechnology investments, and began his career as a scientist at Ferring Pharmaceuticals.

Eric Pauwels Chief Business Officer

Mr. Pauwels became Chief Business Officer in 2020, having initially joined PTC in March 2015 as Senior Vice President and General Manager of the Americas. He has more than 40 years of healthcare experience and has launched over 30 biopharmaceutical products globally, with a significant focus on rare diseases in the last 18 years. Prior to his tenure at PTC, Mr. Pauwels was the Chief Commercial Officer and President of International for NPS Pharmaceuticals from 2011 to 2015. NPS Pharmaceuticals was acquired by Shire in 2015, around the time Mr. Pauwels transitioned to PTC. Before NPS, he was the first Chief Commercial Officer for Shire Human Genetic Therapies Rare Disease Business from 2005 to 2010. He also held global marketing and management roles at companies such as Bayer, Fournier, and Johnson & Johnson.

Lee Golden, M.D. Executive Vice President and Chief Medical Officer

Dr. Golden joined PTC Therapeutics in 2020 as Senior Vice President, Head of Global Clinical Development, and was appointed Chief Medical Officer in 2022, becoming Executive Vice President and Chief Medical Officer in April 2023. He leads global clinical development for PTC's pipeline assets. Prior to PTC, Dr. Golden served as Chief Medical Officer at Espero BioPharma, Inc., a privately held clinical-stage biopharmaceutical company, and as Chief Medical Officer at Gemphire Therapeutics, a clinical-stage biopharmaceutical company. His industry experience spans over 20 years, including senior roles at large pharmaceutical and biotech companies such as Pfizer, Actelion, Elan, Eisai, Mesoblast, and Novartis. He also serves as Chairman of the Advisory Board for Coagulation Sciences LLC.

Neil Almstead, Ph.D. Chief Technical Operations Officer

Dr. Almstead has been with PTC Therapeutics for over 20 years, holding various executive positions since joining in 2000. He was promoted to Chief Technical Operations Officer in January 2019. In this role, he is responsible for overseeing research, manufacturing, and the supply chain for both small-molecule and gene-therapy programs, and is leading the establishment of in-house gene therapy manufacturing. Before joining PTC, Dr. Almstead worked as a project manager at Procter & Gamble.

AI Analysis | Feedback

The key risks to PTC Therapeutics' business are primarily centered on regulatory challenges, pipeline development setbacks, and competitive pressures. 1. **Regulatory Challenges and Loss of Product Approvals:** PTC Therapeutics faces significant and ongoing regulatory hurdles, most notably with its Duchenne muscular dystrophy (DMD) drug, Translarna (ataluren). The company recently withdrew its New Drug Application (NDA) resubmission for Translarna in the United States after the FDA indicated that the submitted data was unlikely to meet the threshold for substantial evidence of effectiveness to support approval. This decision followed a major setback in Europe, where Translarna's conditional marketing authorization was not renewed in late 2024, despite its initial approval in 2014. These developments are highly impactful as Translarna, alongside Emflaza, constituted PTC's top-performing products, and the loss of key market access significantly jeopardizes revenue streams. Furthermore, the company previously faced an FDA denial for its Friedreich's ataxia candidate, vatiquinone, due to insufficient evidence of efficacy. The reliance on successful regulatory approvals means that negative outcomes can materially impact the company's ability to commercialize products and affect its financial health. 2. **Clinical Trial and Regulatory Risks for Pipeline Products:** The successful development and approval of pipeline candidates are critical for PTC Therapeutics' future growth, but this area carries substantial risk. For instance, while PTC518 for Huntington's disease met its primary endpoint in a Phase 2 study by significantly reducing Huntingtin protein levels, the clinical data generated considerable skepticism from investors regarding its ability to demonstrate a clear correlation between protein reduction and clinical outcomes, and its potential to significantly slow disease progression. The mixed results between Stage 2 and Stage 3 patients also suggest complexities in treatment effect, casting doubt on the path to accelerated approval. This investor skepticism led to a notable drop in the company's share price, highlighting the high stakes associated with pipeline development and regulatory alignment. 3. **Competition and Loss of Market Exclusivity:** PTC Therapeutics operates within a highly competitive biopharmaceutical industry, particularly in the rare disease segment. A significant risk is the loss of market exclusivity for key products, such as Emflaza, which has already occurred. This exposes the product to generic competition, potentially eroding market share and pricing power. For new product launches, such as sepiapterin for phenylketonuria (PKU), the company must effectively differentiate its offerings from existing treatments to gain market access and achieve favorable reimbursement. The ongoing threat of new entrants and the development of similar or superior products by competitors necessitate continuous innovation and strong market execution to maintain a competitive edge and ensure long-term revenue potential.

AI Analysis | Feedback

null

AI Analysis | Feedback

PTC Therapeutics focuses on developing treatments for rare disorders, with several key products addressing significant addressable markets globally and in specific regions.

Translarna (ataluren) for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

The global Duchenne muscular dystrophy (DMD) treatment market, which includes nmDMD, was valued at approximately USD 4.79 billion in 2025 and is projected to increase to around USD 19.46 billion by 2034. Translarna specifically targets nonsense mutations, which are applicable to about 10-15% of DMD patients. In 2023, the DMD market in the seven major markets (7MM: U.S., France, Germany, Italy, Spain, U.K., and Japan) was valued at USD 2.3 billion, with projections to reach USD 5.2 billion by 2033. The U.S. alone accounted for approximately USD 1.9 billion of the DMD market in 2024. Translarna generated around USD 235.5 million in sales in Europe in 2025.

Emflaza (deflazacort) for Duchenne Muscular Dystrophy (DMD)

Emflaza is a corticosteroid therapy for the broader Duchenne muscular dystrophy (DMD) market. The global DMD treatment market was valued at approximately USD 4.79 billion in 2025 and is expected to grow to about USD 19.46 billion by 2034. North America held approximately 46% of the global DMD market share in 2024. Emflaza's net product revenue for the full year 2023 was USD 255.1 million.

Waylivra (volanesorsen) for Familial Chylomicronemia Syndrome (FCS)

The global Familial Chylomicronemia Syndrome (FCS) treatment market was valued at approximately USD 15.30 million in 2024 and is projected to reach USD 19.9 million by 2035. Another estimate places the global market at USD 14.23 million in 2024, expected to reach USD 20.83 million by 2032. Waylivra is currently approved in Europe but not in the U.S. The 7MM (U.S., EU4, U.K., and Japan) market for FCS was approximately USD 15 million in 2022.

Evrysdi (risdiplam) for Spinal Muscular Atrophy (SMA)

The global spinal muscular atrophy (SMA) treatment market was estimated at USD 4.40 billion in 2024 and is projected to reach USD 13.09 billion by 2030. Another source projects the market to reach nearly USD 20.06 billion by 2033. North America held the largest revenue share in the SMA treatment market, accounting for 68.4% in 2024. Evrysdi's full-year sales for 2024 were approximately USD 1.8 billion, with forecasts suggesting sales could reach USD 2.9 billion by 2031.

PTC518 for Huntington's Disease (HD)

The global Huntington's disease (HD) treatment market was valued at approximately USD 1.39 billion in 2025 and is projected to grow to USD 4.33 billion by 2034. North America accounted for a significant share of the HD treatment market, with 40.85% in 2024. The U.S. Huntington's Disease treatment market is expected to reach USD 552.5 million by 2033, growing from USD 154.38 million in 2024.

Tegsedi (inotersen) for Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) with Polyneuropathy

Information regarding the specific addressable market size for Tegsedi for hereditary transthyretin amyloidosis with polyneuropathy was not explicitly available in the provided search results.

AI Analysis | Feedback

PTC Therapeutics (PTCT) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:

  1. Global Expansion and Uptake of Sepiapterin (Sephience) for PKU: The successful launch and continued global expansion of Sephience (sepiapterin) for phenylketonuria (PKU) is a significant revenue driver. The drug was launched in the United States and Europe, with additional launches anticipated in Japan and Brazil. Management projects substantial revenue from this product, which generated approximately $111 million in its initial months post-launch in 2025 and is expected to be the primary contributor to product revenue growth in 2026.
  2. Advancement and Potential Accelerated Approval of PTC518 for Huntington's Disease: PTC518, an investigational therapy for Huntington's disease (HD), has shown promising Phase 2 results, meeting its primary endpoint by reducing blood Huntingtin protein levels. The company plans to work with the FDA on an accelerated approval pathway for this treatment. A collaboration agreement with Novartis for the PTC518 program includes potential milestone payments of up to $1.9 billion, indicating its significant financial impact.
  3. Continued Growth and Geographic Expansion of the Duchenne Muscular Dystrophy (DMD) Franchise: Despite facing regulatory setbacks for Translarna in the U.S. and potential generic competition for Emflaza, the DMD franchise continues to be a meaningful revenue contributor. The company's strategy involves driving growth through new patients in existing markets and ongoing geographic expansion for its Duchenne muscular dystrophy therapies, Translarna and Emflaza.
  4. Global Rollout and Expansion of Gene Therapy for AADC Deficiency (Upstaza): The ongoing global rollout of PTC's gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency, Upstaza, is another anticipated growth driver. The company expects to expand this therapy into new territories in the coming years, thereby increasing its patient reach and diversifying revenue streams.

AI Analysis | Feedback

Share Issuance

  • PTC Therapeutics has issued restricted stock units (RSUs) and stock options as inducement grants to new employees, including 14,550 stock options and 17,515 RSUs approved on March 10, 2026, for 18 new hires.
  • A "Post IPO" funding round occurred on May 16, 2023, though the specific dollar amount of shares issued was not disclosed.
  • The company maintains an "Amended and Restated 2016 Employee Stock Purchase Plan" which allows for the issuance of up to 2,000,000 shares of common stock to eligible employees.

Inbound Investments

  • In December 2025, PTC Therapeutics sold the remainder of its Evrysdi® royalty to Royalty Pharma for an upfront payment of $240 million, with potential for up to an additional $60 million in sales-based milestones.
  • A collaboration and license agreement with Novartis for votoplam, which closed in January 2025, generated $998.4 million in collaboration and license revenue for PTC Therapeutics in 2025.
  • Several institutional investors acquired significant stakes in PTC Therapeutics, including Jefferies Financial Group, which purchased approximately $97.2 million worth of shares in Q3 2026, and Palo Alto Investors, which increased its position by approximately $33.1 million in Q3 2025.

Outbound Investments

  • In 2024, PTC Therapeutics acquired Censa Pharmaceuticals for $250 million, adding the phase 3-ready asset CTRX-100 for phenylketonuria to its pipeline.

Capital Expenditures

  • PTC Therapeutics' capital expenditures were approximately $8.79 million in fiscal year 2025.
  • In the last 12 months, the company reported capital expenditures of -$8.86 million.
  • Annual capital expenditures were $28 million in 2021, $32 million in 2022, and $28 million in 2023.

Better Bets vs. PTC Therapeutics (PTCT)

Peer Outperformance in Pharmaceuticals

PTCT has outperformed 73% of its 59 Pharmaceuticals peers over 5Y. Pharmaceuticals ranks 7th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Pharmaceuticals constituents that PTCT has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
45%
of 69 industry peers · -21.5% return
3Y
86%
of 64 industry peers · 194.4% return
5Y
73%
of 59 industry peers · 52.8% return
No Pharmaceuticals peer with a comparable growth profile has beaten PTCT by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Pharmaceuticals is PTCT's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 20.4%83.0%196.8% CAH 525% · MCK 393% · COR 197%
Health Care Services 20 30.3%21.9%13.8% RDNT 157% · HIMS 130% · DGX 93%
Health Care Facilities 26 12.5%14.3%-7.7% THC 245% · NHC 223% · EHC 185%
Managed Health Care 8 56.6%-8.0%-9.8% OSCR 159% · HQY 55% · ELV 1%
Health Care Equipment 49 -0.4%5.4%-17.6% GKOS 394% · UFPT 358% · TMDX 319%
Health Care Supplies 11 24.2%1.3%-40.0% LNTH 252% · HAE 120% · MMSI 26%
Pharmaceuticals ← 60 -16.4%3.2%-41.7% LQDA 1121% · KNSA 653% · XERS 611%
Life Sciences Tools & Services 110 -19.2%-24.9%-75.1% AXGN 462% · MEDP 186% · NTRA 176%
Biotechnology 370 -33.9%-40.4%-84.4% ELVN 1240% · TRVI 1212% · DNTH 1117%
Health Care Technology 23 -20.6%-60.0%-86.6% VEEV -10% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

PTCTSRPTBIIBBMRNRAREVRTXMedian
NamePTC Ther.Sarepta .Biogen BioMarin.Ultragen.Vertex P. 
Mkt Price59.9114.66251.3961.4017.74539.3560.66
Mkt Cap5.01.637.211.91.8136.78.4
Rev LTM1,1561,95610,2973,65573012,9522,806
Op Inc LTM138-81,807181-4674,288160
FCF LTM-411711,644554-4473,202363
FCF 3Y Avg41-2321,892560-4511,729301
CFO LTM101862,247677-4373,695431
CFO 3Y Avg183-1372,276668-4342,190426

Growth & Margins

PTCTSRPTBIIBBMRNRAREVRTXMedian
NamePTC Ther.Sarepta .Biogen BioMarin.Ultragen.Vertex P. 
Rev Chg LTM-35.1%-18.9%2.3%18.1%15.8%10.5%6.4%
Rev Chg 3Y Avg25.1%25.5%1.1%16.6%21.3%10.3%18.9%
Rev Chg Q69.6%-4.5%10.6%32.0%8.1%11.8%11.2%
QoQ Delta Rev Chg LTM14.6%-0.9%2.7%7.3%1.8%2.9%2.8%
Op Inc Chg LTM-85.0%90.2%-29.2%-78.4%14.2%4,760.7%-7.5%
Op Inc Chg 3Y Avg270.7%1.5%0.9%49.1%7.4%1,548.2%28.3%
Op Mgn LTM12.0%-0.4%17.6%4.9%-64.0%33.1%8.5%
Op Mgn 3Y Avg16.5%0.3%22.2%14.8%-84.3%22.4%15.7%
QoQ Delta Op Mgn LTM0.4%2.7%-1.7%0.6%9.7%-4.8%0.5%
CFO/Rev LTM0.9%9.5%21.8%18.5%-59.9%28.5%14.0%
CFO/Rev 3Y Avg7.1%-7.4%22.8%21.0%-70.2%17.4%12.3%
FCF/Rev LTM-3.6%8.8%16.0%15.2%-61.2%24.7%12.0%
FCF/Rev 3Y Avg-3.3%-12.2%18.9%17.6%-73.1%13.5%5.1%

Valuation

PTCTSRPTBIIBBMRNRAREVRTXMedian
NamePTC Ther.Sarepta .Biogen BioMarin.Ultragen.Vertex P. 
Mkt Cap5.01.637.211.91.8136.78.4
P/S4.30.83.63.32.510.63.4
P/Op Inc36.1-184.920.665.8-3.931.926.2
P/EBIT44.1-188.749.565.9-4.130.037.0
P/E-47.2-13.5106.9-621.8-3.534.4-8.5
P/CFO476.98.416.517.6-4.137.017.1
Total Yield-2.1%-7.4%0.9%-0.2%-28.9%2.9%-1.1%
Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-0.5%-5.1%7.4%5.0%-17.6%1.5%0.5%
D/E0.10.70.20.40.00.00.2
Net D/E-0.30.10.20.3-0.10.00.1

Returns

PTCTSRPTBIIBBMRNRAREVRTXMedian
NamePTC Ther.Sarepta .Biogen BioMarin.Ultragen.Vertex P. 
1M Rtn-2.6%-17.3%7.7%12.3%17.7%7.5%7.6%
3M Rtn-18.7%-25.7%13.5%-11.4%-32.4%-2.3%-15.1%
6M Rtn-15.6%-14.4%33.9%22.3%-24.1%25.3%4.0%
12M Rtn-21.9%-15.9%48.9%13.4%-46.0%23.8%-1.3%
3Y Rtn192.8%-82.4%10.3%-29.8%-55.6%53.9%-9.8%
1M Excs Rtn-1.0%-19.7%7.2%12.6%14.6%8.7%8.0%
3M Excs Rtn-12.1%-20.8%20.2%-6.3%-27.0%2.8%-9.2%
6M Excs Rtn-15.4%-14.1%34.1%22.5%-23.9%25.5%4.2%
12M Excs Rtn-31.8%-27.7%41.5%1.6%-56.6%13.1%-13.0%
3Y Excs Rtn155.6%-150.3%-55.2%-94.5%-117.9%-26.1%-74.8%

FDA Approved Drugs Data

Expand for More
Post-Approval Fwd Returns
FDA
App #
Brand
Name
Generic
Name
Dosage
Form
FDA
Approval
3M
Rtn
6M
Rtn
1Y
Rtn
2Y
Rtn
Total
Rtn
NDA219666  SEPHIENCEsepiapterinpowder728202551.3%71.9%70.0%35.8%35.8%
NDA208685  EMFLAZAdeflazacortsuspension2092017-6.2%32.8%66.4%115.1%335.8%
NDA208684  EMFLAZAdeflazacorttablet2092017-6.2%32.8%66.4%115.1%335.8%
Collapse to Preview
Post-Approval Fwd Returns
FDA
App #
Brand
Name
Generic
Name
Dosage
Form
FDA
Approval
3M
Rtn
6M
Rtn
1Y
Rtn
2Y
Rtn
Total
Rtn
NDA219666  SEPHIENCEsepiapterinpowder728202551.3%71.9%70.0%35.8%35.8%
NDA208685  EMFLAZAdeflazacortsuspension2092017-6.2%32.8%66.4%115.1%335.8%
NDA208684  EMFLAZAdeflazacorttablet2092017-6.2%32.8%66.4%115.1%335.8%

Clinical Pipeline

Drug CandidateIndicationPhase 3 TrialsEst. Primary Completion
Vatiquinone (PTC743)Friedreich Ataxia1Dec 2027
Sepiapterin (PTC923)Phenylketonuria2Feb 2031
Active Phase 3 studies led by the company. Source: ClinicalTrials.gov · Updated 8/28/2026

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Collaboration and license revenue9980100 55
Royalty revenue244204169 55
Translarna235321333  
Emflaza146207255  
Sephience11100  
Upstaza/Kebilidi571719  
All other products373731  
Manufacturing revenue028 0
Translarna France-991923  
Life science   699 
Net product revenue    429
Total1,731807938699539


Net Income by Segment
$ Mil20242022
Life science-363-559
Total-363-559


Price Behavior

Price Behavior
Market Price$60.23 
Market Cap ($ Bil)5.0 
First Trading Date06/20/2013 
Distance from 52W High-32.7% 
   50 Days200 Days
DMA Price$63.64$69.95
DMA Trenddowndown
Distance from DMA-5.4%-13.9%
 3M1YR
Volatility44.2%43.1%
Downside Capture173.39126.02
Upside Capture124.3785.69
Correlation (S&P 500)35.8%28.0%
PTCT Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta2.131.171.090.500.801.04
Up Beta-1.60-1.76-0.430.781.330.96
Down Beta1.101.051.680.37-0.170.71
Up Capture235%120%99%29%73%273%
Bmk +ve Days12182862130427
Stock +ve Days11192960123377
Down Capture288%204%170%66%107%105%
Bmk -ve Days10253664121325
Stock -ve Days11243565126370

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with PTCT
PTCT-20.4%43.1%-0.42-
Sector ETF (XLV)21.5%17.0%0.9631.8%
Equity (SPY)10.9%13.8%0.4927.4%
Gold (GLD)-8.2%29.0%-0.3016.4%
Commodities (DBC)28.8%21.5%1.07-17.2%
Real Estate (VNQ)11.2%14.2%0.5017.8%
Bitcoin (BTCUSD)-29.6%43.7%-0.6916.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with PTCT
PTCT8.9%55.3%0.36-
Sector ETF (XLV)8.0%15.4%0.3330.0%
Equity (SPY)11.0%17.3%0.4630.7%
Gold (GLD)14.5%19.2%0.604.2%
Commodities (DBC)6.8%19.6%0.24-3.4%
Real Estate (VNQ)1.1%19.0%-0.0527.6%
Bitcoin (BTCUSD)-0.0%51.4%0.1820.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with PTCT
PTCT28.0%62.2%0.64-
Sector ETF (XLV)12.1%16.8%0.5929.5%
Equity (SPY)14.9%18.0%0.7030.2%
Gold (GLD)10.9%16.6%0.531.7%
Commodities (DBC)7.2%18.2%0.313.4%
Real Estate (VNQ)5.8%20.7%0.2423.6%
Bitcoin (BTCUSD)57.1%66.3%0.979.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity7.8 Mil
Short Interest: % Change Since 10152026-6.3%
Average Daily Volume1.0 Mil
Days-to-Cover Short Interest7.5 days
Basic Shares Quantity83.5 Mil
Short % of Basic Shares9.3%

Earnings Returns History

Updated 11/9/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
10/29/2026-7.0%1.9% 
7/30/2026-9.9%-6.2%-7.2%
5/7/202614.3%12.8%9.9%
2/19/20261.1%-2.6%-6.6%
11/4/20256.0%9.0%14.1%
8/7/2025-9.9%-3.3%13.1%
5/6/202512.6%28.2%42.9%
2/27/20259.3%4.4%7.3%
...
SUMMARY STATS   
# Positive161513
# Negative91011
Median Positive6.1%5.6%9.9%
Median Negative-7.3%-4.7%-7.2%
Max Positive14.3%31.9%45.9%
Max Negative-22.7%-24.6%-24.0%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
10/29/2026-7.0%1.9% 
7/30/2026-9.9%-6.2%-7.2%
5/7/202614.3%12.8%9.9%
2/19/20261.1%-2.6%-6.6%
11/4/20256.0%9.0%14.1%
8/7/2025-9.9%-3.3%13.1%
5/6/202512.6%28.2%42.9%
2/27/20259.3%4.4%7.3%
11/7/20243.1%-1.4%11.9%
8/8/2024-3.6%1.8%-3.2%
4/25/202412.1%31.9%45.9%
2/29/202413.3%9.1%1.4%
1/8/20247.5%-2.0%-4.0%
10/26/2023-22.7%-24.6%-10.3%
8/3/2023-4.0%0.8%-0.6%
4/27/20234.7%6.1%-19.0%
2/21/2023-1.1%-2.3%3.6%
10/27/2022-13.7%-18.7%-9.2%
8/4/20228.7%5.6%5.4%
5/3/20222.7%-7.0%-24.0%
2/22/2022-7.3%-10.8%-4.2%
10/28/20214.1%14.1%1.2%
7/29/20210.2%4.3%10.7%
5/4/20216.3%0.7%0.1%
2/25/20213.5%4.9%-10.8%
SUMMARY STATS   
# Positive161513
# Negative91011
Median Positive6.1%5.6%9.9%
Median Negative-7.3%-4.7%-7.2%
Max Positive14.3%31.9%45.9%
Max Negative-22.7%-24.6%-24.0%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202610/29/202610-Q
06/30/202607/30/202610-Q
03/31/202605/07/202610-Q
12/31/202502/19/202610-K
09/30/202511/04/202510-Q
06/30/202508/07/202510-Q
03/31/202505/06/202510-Q
12/31/202402/27/202510-K
09/30/202411/07/202410-Q
06/30/202408/08/202410-Q
03/31/202404/25/202410-Q
12/31/202302/29/202410-K
09/30/202310/26/202310-Q
06/30/202308/03/202310-Q
03/31/202304/27/202310-Q
12/31/202202/21/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202610/29/202610-Q
06/30/202607/30/202610-Q
03/31/202605/07/202610-Q
12/31/202502/19/202610-K
09/30/202511/04/202510-Q
06/30/202508/07/202510-Q
03/31/202505/06/202510-Q
12/31/202402/27/202510-K
09/30/202411/07/202410-Q
06/30/202408/08/202410-Q
03/31/202404/25/202410-Q
12/31/202302/29/202410-K
09/30/202310/26/202310-Q
06/30/202308/03/202310-Q
03/31/202304/27/202310-Q
12/31/202202/21/202310-K
09/30/202210/27/202210-Q
06/30/202208/04/202210-Q
03/31/202205/03/202210-Q
12/31/202102/22/202210-K
09/30/202110/28/202110-Q
06/30/202107/29/202110-Q
03/31/202105/04/202110-Q
12/31/202002/25/202110-K
09/30/202010/29/202010-Q
06/30/202008/05/202010-Q
03/31/202004/30/202010-Q
12/31/201903/02/202010-K

Recent Forward Guidance

Updated 11/2/2026

Latest: Q3 2026 Earnings Reported 10/29/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Projected non-cash, stock-based compensation expenseReported 95.00 Mil    
2026 Total RevenueReported1.29 Bil1.30 Bil1.32 Bil6.1% RaisedGuidance: 1.23 Bil for 2026
2026 Product RevenueReported960.00 Mil975.00 Mil990.00 Mil8.3% RaisedGuidance: 900.00 Mil for 2026
2026 Projected GAAP R&D and SG&A ExpenseReported775.00 Mil795.00 Mil815.00 Mil0.0% AffirmedGuidance: 795.00 Mil for 2026
2026 Projected non-GAAP R&D and SG&A expenseReported680.00 Mil700.00 Mil720.00 Mil0.0% AffirmedGuidance: 700.00 Mil for 2026


Prior: Q2 2026 Earnings Reported 7/30/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Total RevenueReported1.18 Bil1.23 Bil1.28 Bil8.8% RaisedGuidance: 1.13 Bil for 2026
2026 Total Product RevenueReported850.00 Mil900.00 Mil950.00 Mil12.5% RaisedGuidance: 800.00 Mil for 2026
2026 GAAP R&D and SG&A ExpenseReported775.00 Mil795.00 Mil815.00 Mil0 AffirmedGuidance: 795.00 Mil for 2026
2026 Non-GAAP R&D and SG&A ExpenseReported680.00 Mil700.00 Mil720.00 Mil0 AffirmedGuidance: 700.00 Mil for 2026

Insider Activity

Updated 11/18/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Boulding, Mark ElliottEXEC. VP AND CLODirectSell1118202661.882,812174,0136,514,484Form
2Schmertzler, MichaelSee footnoteSell1016202659.612,500149,03776,998,035Form
3Boulding, Mark ElliottEXEC. VP AND CLODirectSell1013202664.2619212,3386,764,779Form
4Schmertzler, MichaelSee footnoteSell1009202663.392,500158,48082,035,316Form
5Boulding, Mark ElliottEXEC. VP AND CLODirectSell1007202664.1643527,9106,754,252Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Boulding, Mark ElliottEXEC. VP AND CLODirectSell1118202661.882,812174,0136,514,484Form
2Schmertzler, MichaelSee footnoteSell1016202659.612,500149,03776,998,035Form
3Boulding, Mark ElliottEXEC. VP AND CLODirectSell1013202664.2619212,3386,764,779Form
4Schmertzler, MichaelSee footnoteSell1009202663.392,500158,48082,035,316Form
5Boulding, Mark ElliottEXEC. VP AND CLODirectSell1007202664.1643527,9106,754,252Form
6Boulding, Mark ElliottEXEC. VP AND CLODirectSell1007202664.031,638104,8816,740,566Form
7Steele, Glenn JR MD PhdDirectSell1002202665.1612,000781,9201,466,100Form
8Schmertzler, MichaelSee footnoteSell918202667.8510,000678,53387,978,197Form
9Schmertzler, MichaelSee footnoteSell918202667.1210,000671,19587,697,886Form
10Schmertzler, MichaelSee footnoteSell911202667.3410,000673,40088,659,440Form
11Schmertzler, MichaelSee footnoteSell911202667.8410,000678,40389,996,583Form
12Schmertzler, MichaelSee footnoteSell828202671.5812,500894,78495,677,002Form
13Schmertzler, MichaelSee footnoteSell828202672.9412,500911,72598,400,266Form
14Schmertzler, MichaelSee footnoteSell821202671.1112,500888,85896,821,069Form
15Schmertzler, MichaelSee footnoteSell821202673.3212,500916,554100,754,470Form
16Boulding, Mark ElliottEXEC. VP AND CLODirectSell819202672.572,813204,1277,639,134Form
17Klein, Matthew BCHIEF EXECUTIVE OFFICERDirectSell806202668.5710,292705,72226,321,829Form
18Gravier, PierreCHIEF FINANCIAL OFFICERDirectSell716202680.353,494280,7436,748,275Form
19Smith, Mary LDirectSell713202690.0015,8341,425,0601,963,170Form
20Almstead, Neil GregoryCHIEF TECHNICAL OPS OFFICERDirectSell713202690.252,464222,3765,441,985Form
21Almstead, Neil GregoryCHIEF TECHNICAL OPS OFFICERDirectSell708202688.8924,6132,187,7455,359,723Form
22Boulding, Mark ElliottEXEC. VP AND CLODirectSell708202685.085,079432,1188,956,463Form
23Almstead, Neil GregoryCHIEF TECHNICAL OPS OFFICERDirectSell708202686.0022,1611,905,7365,185,416Form
24Almstead, Neil GregoryCHIEF TECHNICAL OPS OFFICERDirectSell630202685.268,130693,1515,127,189Form
25Almstead, Neil GregoryCHIEF TECHNICAL OPS OFFICERDirectSell626202685.9720,9601,801,8575,169,764Form
26Almstead, Neil GregoryCHIEF TECHNICAL OPS OFFICERDirectSell626202685.035,323452,6075,113,359Form
27Almstead, Neil GregoryCHIEF TECHNICAL OPS OFFICERDirectSell624202680.9023,7491,921,3784,865,296Form
28Utter, Christine MarieSVP, CHIEF ACCOUNTING OFFICERDirectSell622202675.5619,6861,487,4745,304,236Form
29Boulding, Mark ElliottEXEC. VP AND CLODirectSell622202678.6510,462822,8688,279,959Form
30Pauwels, EricCHIEF BUSINESS OFFICERDirectSell612202675.0021,2771,595,7755,505,825Form
31Boulding, Mark ElliottEXEC. VP AND CLODirectSell519202672.182,812202,9587,593,747Form
32Klein, Matthew BCHIEF EXECUTIVE OFFICERDirectSell515202672.9512,572917,15428,742,973Form
33Boulding, Mark ElliottEXEC. VP AND CLODirectSell512202678.973,540279,5708,309,079Form
34Klein, Matthew BCHIEF EXECUTIVE OFFICERDirectSell423202670.912,850202,09427,943,504Form
35Boulding, Mark ElliottEXEC. VP AND CLODirectSell408202669.452,265157,2937,306,463Form
36Golden, Lee ScottEVP & CHIEF MEDICAL OFFICERDirectSell406202667.9982956,3645,379,029Form
37Almstead, Neil GregoryCHIEF TECHNICAL OPS OFFICERDirectSell403202669.0452,0033,590,2434,151,807Form
38Klein, Matthew BCHIEF EXECUTIVE OFFICERDirectSell313202664.082,662170,58125,434,634Form
39Okey, StephanieDirectSell312202670.0015,1671,061,690560,000Form
40Okey, StephanieDirectSell309202663.386,333401,386507,040Form
41Golden, Lee ScottEVP & CHIEF MEDICAL OFFICERDirectSell309202663.3810,000633,8005,066,851Form
42Almstead, Neil GregoryCHIEF TECHNICAL OPS OFFICERSpouseSell309202663.383,989252,823173,471Form
43Boulding, Mark ElliottEXEC. VP AND CLODirectSell223202669.483,019209,7637,310,215Form
44Boulding, Mark ElliottEXEC. VP AND CLODirectSell219202669.363,081213,6987,506,902Form
45Boulding, Mark ElliottEXEC. VP AND CLODirectSell219202669.292,813194,9147,712,875Form
46Pauwels, EricCHIEF BUSINESS OFFICERDirectSell112202678.701,02480,5896,307,097Form
47Pauwels, EricCHIEF BUSINESS OFFICERDirectSell112202677.411,722133,3006,282,983Form
48Boulding, Mark ElliottEXEC. VP AND CLODirectSell112202677.932,314180,3208,674,079Form
49Utter, Christine MarieSVP, CHIEF ACCOUNTING OFFICERDirectSell112202676.451,03479,0495,557,380Form
50Pauwels, EricCHIEF BUSINESS OFFICERDirectSell112202676.504,602352,0576,340,931Form
51Klein, Matthew BCHIEF EXECUTIVE OFFICERDirectSell112202676.452,514192,19530,155,932Form
52Golden, Lee ScottEVP & CHIEF MEDICAL OFFICERDirectSell112202676.4586666,2067,066,121Form
53Boulding, Mark ElliottEXEC. VP AND CLODirectSell112202676.564,033308,7608,699,029Form
54Almstead, Neil GregoryCHIEF TECHNICAL OPS OFFICERDirectSell112202676.4588167,3528,806,734Form
55Almstead, Neil GregoryCHIEF TECHNICAL OPS OFFICERSpouseSell112202676.45594,511519,172Form
56Boulding, Mark ElliottEXEC. VP AND CLODirectSell106202675.552,266171,1929,133,840Form
57Reeve, EmmaDirectSell106202676.0073455,784810,616Form
58Steele, Glenn JR MD PhdDirectSell106202676.3512,000916,2001,412,475Form
59Klein, Matthew BCHIEF EXECUTIVE OFFICERDirectSell102202676.648,089619,94126,201,300Form
60Pauwels, EricCHIEF BUSINESS OFFICERDirectSell1223202577.2620,5081,584,3505,436,681Form
61Pauwels, EricCHIEF BUSINESS OFFICERDirectSell1219202575.063,202240,3515,282,383Form
62Pauwels, EricCHIEF BUSINESS OFFICERDirectSell1219202575.4340,2903,038,9245,307,973Form
63Reeve, EmmaDirectSell1205202578.6273357,628524,081Form
64Klein, Matthew BCHIEF EXECUTIVE OFFICERDirectSell1203202579.073,428271,05227,671,653Form
65Almstead, Neil GregoryCHIEF TECHNICAL OPS OFFICERDirectSell1126202583.4471,9286,001,9328,396,513Form
66Jacobson, Allan StevenDirectSell1126202583.5514,1991,186,2821,457,977Form
67Almstead, Neil GregoryCHIEF TECHNICAL OPS OFFICERDirectSell1126202580.1835,5722,852,0318,067,738Form
68Jacobson, Allan StevenDirectSell1126202580.1411,801945,7361,398,529Form
69Reeve, EmmaDirectSell1125202579.5010,000795,000529,947Form
70Boulding, Mark ElliottEXEC. VP AND CLODirectSell1119202575.992,812213,6877,895,548Form
71Reeve, EmmaDirectSell1114202574.507,333546,308496,617Form
72Reeve, EmmaDirectSell1031202569.5015,6661,088,787463,287Form

Investor Activity (13F)

Updated Nov 19, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Defilade Capital Management, L.P.$41.1 Mil5.8%31New13F
Sector Gamma AS$5.1 Mil1.2%42ADD +21.1%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Defilade Capital Management, L.P.$41.1 Mil5.8%31New13F
Sector Gamma AS$5.1 Mil1.2%42ADD +21.1%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Avoro Capital Advisors LLC$52.0 Mil0.5%33Exited13F
MPM Bioimpact LLC$32.7 Mil3.7%38Exited13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Defilade Capital Management, L.P.$41.1 Mil5.8%31New13F
Sector Gamma AS$5.1 Mil1.2%42ADD +21.1%13F
Core Cache Last Updated: 11/18/2026